TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00481832
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4 gm /m² IV over 2 hours on day 8
Study: NCT00543842
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Starting Dose 650 mg/m\^2 By Mouth Twice Daily Monday-Friday x 6 Weeks
Study: NCT06013735
Drug: guava leaves aqueous extract
Normalized name: guava extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: guava leaves aqueous extract mouth rinse (0.5%)
Study: NCT04383743
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04383743
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01654354
Drug: NEOVIST 370 INJ.(Iopromide 768.86mg)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01654354
Drug: Ultravist 370 INJ.(Iopromide 768.86mg)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04139330
Drug: NPC-06
Normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infuse NPC-06 intravenously
Study: NCT05414461
Drug: Combinations
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 inhibitor-based combinaiton treatment
Study: NCT00215904
Drug: D-serine (~2g/day)
Normalized name: D-Serine
DrugBank: D-Serine (DB03929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 6 weeks treatment arms. One arm: adjuvant treatment with D-serine (\~2g/day). Second arm : adjuvant treatment with placebo (\~2g/day).
Study: NCT02884440
Drug: TAP block placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02884440
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction PROPOFOL 10mg/ml REMIFENTANIL 50 μg/ml CISATRACURIUM 2mg/ml if necessary DEXAMETHASONE 8 mg KETAMINE 0,15mg/kg Maintenance PROPOFOL 10mg/ml REMIFENTANIL 50 μg/ml
Study: NCT04039087
Drug: Placebo Oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule taken by mouth thrice daily
Study: NCT02647099
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02647099
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03377387
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine will be taken orally in AM and PM (at the assigned dose per cohort) 7 days on and 7 days off. Phase II MD 1000mg BID of capecitabine.
Study: NCT02161614
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00743184
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical placebo is also provided and reconstituted using diluent containing 0.1% saline solution.
Study: NCT04188548
Drug: LY3484356
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01643070
Drug: Capecitabine, Oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy - Induction XELOX (Capecitabine 1250 mg/m2 PO twice daily on D1-14 and oxaliplatin 130 mg/m2 on D1, every 3 weeks for 2 cycles) Preoperative chemoradiotherapy - XELOX RT (Capecitabine 825 mg/m2 PO twice daily during radiotherapy and oxaliplatin 50 mg/m2/day on weekly.)
Study: NCT03808610
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03808610
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01600014
Drug: Vehicle gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical field treatment once daily for 3 consecutive days within a 25 cm2 treatment area on the face or scalp of AKs present or emerging after an initial treatment with ingenol mebutate gel, 0.015%
Study: NCT03591133
Drug: TS-143
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03591133
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03333343
Drug: EGF816
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study Drug
Study: NCT04524273
Drug: IV Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive IV placebo matched to inebilizumab
Study: NCT04539496
Drug: XZP-3287
Approvals — FDA: no, EMA: no, PMDA: no
Description: * 20-560 mg QD, oral~* 240-480 mg BID, oral
Study: NCT04539496
Drug: XZP-3287
Approvals — FDA: no, EMA: no, PMDA: no
Description: 480 mg BID, oral
Study: NCT00018694
Drug: Chenodeoxycholic Acid
Normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00005089
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m\^2 on day 10 of cycle 1, then on day 21 of cycles 2-3.
Study: NCT00005089
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m\^2 on day 10 of cycle 1, then on day 21 of cycles 2-3.
Study: NCT02647125
Drug: Huachansu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huachansu 20 ml/m2/d, intervenous infusion, once a day, 5 times per week, during the period of radiation.
Study: NCT00354627
Drug: TMC125
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg b.i.d. till commercially available.
Study: NCT00596414
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02365649
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Dosing
Study: NCT02365649
Drug: ABT-494
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Dosing
Study: NCT02226367
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: study drug arm placebo
Study: NCT00554840
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: At the end of Pre-med week 1, subjects will receive study medication with the target quit date being the following week. Subjects will be randomized to receive either active drug or matching placebo capsules using the following titration schedule: 0.5mg for three days, 0.5mg twice daily for the next four days, then 1mg twice daily for the rest of the treatment phase. Subjects will be evaluated weekly for abstinence through self report, end expired CO and urine dipstick for cotinine.
Study: NCT04398771
Drug: Rosuvastatin/Valsartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rovatitan QD for 12 weeks
Study: NCT04068194
Drug: Peposertib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT02769689
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Included patients will receive either methylprednisolone (1 gramme, 1 day every 4 weeks for a total of 3 grammes) or undistinguishable capsules of placebo
Study: NCT02769689
Drug: fingolimob (FTY)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every patient will initiate a treatment with FTY 7 weeks after the last NTZ perfusion. Methylprednisolone or placebo will be taken 4, 8 and 12 weeks (W4, W8 and W12) after NTZ discontinuation.
Study: NCT04647708
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo matched to M5049.
Study: NCT00087685
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg by mouth Daily
Study: NCT02400359
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a placebo oral pill that is a visual replica of the Lorcaserin medication but with no active ingredients.
Study: NCT01000623
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT04789005
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norepinephrine 8mcg was administered manually by the anaesthesiologist every time the SBP was 20% lower than baseline and the HR ≥60 bpm.
Study: NCT04421105
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02028806
Drug: mFOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
Study: NCT02243189
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single nasal dose of placebo matching to JNJ-43260295 will be given.
Study: NCT00758420
Drug: Agitated Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 u/mL normal heparinized saline solution, up to 20 mL, one treatment session
Study: NCT04299373
Drug: Alcohol: Oral administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who plan to undergo bariatric surgery will consume a controlled dose of alcohol orally.
Study: NCT04299373
Drug: Alcohol: Intravenous administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who plan to undergo bariatric surgery will be infused with alcohol intravenously.
Study: NCT01551381
Drug: EV-077
Normalized name: Summer's Eve Medicated
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice daily oral administration
Study: NCT01551381
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice daily oral administration
Study: NCT03044730
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT04770701
Drug: Ahah Drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: - Composition Ahah containing concentrated extracts of plants: Eclipta prostrata 200mg, dioscorea cirrhosa 200mg, phyllanthus urinaria 150mg, adenosma glutinosum 150mg, impatiens balsamina 75mg and ascorbic acid 250mg~-Take 1tablet x 2 times / 24 hours. Maintained for 9 months.
Study: NCT00887601
Drug: MK3134
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose 25 mg (5 x 5 mg) MK3134 capsules in one of the four treatment periods.
Study: NCT00887601
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules only in one of the four treatment periods.
Study: NCT04104321
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo BID
Study: NCT00887601
Drug: MK3134
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of 1 mg, 5 mg, or 25 mg MK3134 capsules in the assigned treatment periods
Study: NCT04169126
Drug: F-18 PMPBB3
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study will enroll 200 patients with prodromal AD and AD dementia and 100 normal controls, men and women aged 55-80 years across core clinical criteria of prodromal AD and mild AD dementia based on IWG-2 criteria.
Study: NCT01917058
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01280006
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. Then they will be tested with an exposure of intermittent hypoxia.~Indomethacin: 50 mg, Oral, three times per day for five days.
Study: NCT01280006
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. Then they will be tested with an exposure of intermittent hypoxia.~Celecoxib: 200 mg, Oral, two times per day for five days with a visually matching sequential placebo in between of two doses.
Study: NCT01280006
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. Then they will be tested with an exposure of intermittent hypoxia.~Placebo: Oral, three times per day for five days.
Study: NCT03269526
Drug: EGFR BATs after standard of care chemo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive one dose of standard of care chemotherapy prior to twice weekly or weekly infusions of EGFR BATs for 4 weeks.
Study: NCT03107481
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 1g IV
Study: NCT02441387
Drug: Antidepressant
Normalized name: Antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 50-250mg/day for 1 year or Escitalopram 10-20mg/day for 1 year or Mirtazapine 15-45mg/day for 1 year or Venlafaxine 37,5-300mg/day for 1 year or Lithium 300-900mg/day for 1 year.
Study: NCT04172675
Drug: Investigator Choice (Gemcitabine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator's Choice treatment will be given once weekly for at least 4 doses of induction followed by monthly maintenance for at least 6 months.
Study: NCT04172675
Drug: Investigator Choice (Mitomycin C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator's Choice treatment will be given once weekly for at least 4 doses of induction followed by monthly maintenance for at least 6 months.
Study: NCT03009058
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard of Care chemotherapy
Study: NCT03009058
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard of Care chemotherapy
Study: NCT03009058
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard of Care chemotherapy
Study: NCT03596502
Drug: Direct oral anticoagulants (DOACs)
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure to DOACs will be defined as a new prescription for apixaban (ATC B01AF02), dabigatran (ATC B01AE07), or rivaroxaban (ATC B01AF01) at cohort entry date in patients diagnosed with non-valvular atrial fibrillation.
Study: NCT00711698
Drug: nurse-administered intermittent IV bolus opioid therapy (NAIBOD)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this arm patients will receive the current standard of care of IV bolus narcotic therapy
Study: NCT01535040
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo by mouth through completion of 12 weeks.
Study: NCT02059174
Drug: MK-1293
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-1293 0.4 units/kg administered subcutaneously
Study: NCT02059174
Drug: EU-Lantus™
Approvals — FDA: no, EMA: no, PMDA: no
Description: EU-Lantus™ 0.4 units/kg administered subcutaneously
Study: NCT02059174
Drug: Novolog™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive an intravenous infusion of insulin aspart (Novolog™ or other rapid-acting insulin analog) for several hours prior to MK-1293 or EU-Lantus™ dosing in each dosing period to meet basal insulin requirements
Study: NCT01651728
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet 20 mg once daily for 30 days
Study: NCT01651728
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily for 30 days
Study: NCT00540787
Drug: Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone will be taken at 600 mg per day for 21 days (as a loading dose) followed by 1.4g per week or 200mg per day. The daily dose may be increased to 300mg or 2.1g per week.
Study: NCT02632760
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo - no active drug
Study: NCT01901159
Drug: RO4995819
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral doses of RO4995819 (tablet)
Study: NCT00712764
Drug: Adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01901159
Drug: RO4995819
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral doses of RO4995819 (capsule)
Study: NCT00712764
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00756223
Drug: Arm A
Normalized name: Warm antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation Arm A (4 weeks)
Study: NCT00756223
Drug: Arm B
Normalized name: arm brace
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation Arm B (3 weeks)
Study: NCT01736176
Drug: Levodopa-Carbidopa Intestinal Gel
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa-carbidopa intestinal gel (LCIG) for upper-intestinal infusion is a suspension of levodopa (20 mg/mL) and carbidopa monohydrate (5 mg/mL) in an aqueous gel, administered continuously by a portable pump via a percutaneous endoscopic gastrojejunostomy (PEG-J) tube.~The rate of LCIG infusion was expected to be within the range of 1 to 10 mL/hour (20 to 200 mg of levodopa/hour) in most instances over a period of 16 consecutive hours.
Study: NCT01736176
Drug: Levodopa-carbidopa Immediate Release (LC-IR) Tablets
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: After LCIG initiation, participants could take prescribed oral levodopa-carbidopa immediate or continuous release (i.e., oral LC prescribed by the investigator) for nighttime use.
Study: NCT00782535
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled solution, single dose of placebo
Study: NCT00781768
Drug: Standard PO (Zofran + Dexamethason)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 10 mg (dose blinded) in 50 ml D5W IVPB over 15 minutes daily + ondansetron 8mg PO q 8 hours - repeated qd of the preparative regimen and for 1 day after completion. A placebo capsule will be given daily on each day of the preparative regimen plus 3 days after. Antiemetic therapy will start a minimum of 30 minutes prior to and continued for 24 hours after completion of the preparative regimen.
Study: NCT02447393
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02466815
Drug: JNJ-42756493 Current Clinical Formulation (G-018)
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as current clinical formulation (G-018) in treatment A in either period 1, 2 or 3 as per treatment sequence.
Study: NCT03055806
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo caplet(s)
Study: NCT00125138
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syrup formulation
Study: NCT02630459
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo via subcutaneous injection
Study: NCT06300866
Drug: Test
Normalized name: Testro
Approvals — FDA: no, EMA: no, PMDA: no
Description: test toothpaste containing 0.45% stannous fluoride
Study: NCT02114359
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine : 1250mg/m2 po bid D1-14 q3wks (if Ccr \<60ml/min, 1000mg/m2 po bid)
Study: NCT00966654
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 pmol/kg/min (5 ng/kg/min) saline infused continuously over 72 hours.
Study: NCT02466815
Drug: JNJ-42756493 Prototype Formulation I (G-025)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as Prototype Formulation I (G-025) in treatment B in either period 1, 2 or 3 as per treatment sequence.
Study: NCT02466815
Drug: JNJ-42756493 Prototype Formulation II (G-025)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as Prototype Formulation II (G-025) in treatment C in either period 1, 2 or 3 as per treatment sequence.
Study: NCT02156843
Drug: Pyridorin
Normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mg BID (twice daily, every 12 hours), oral capsule taken until end stage renal disease or death occurs, or the study is terminated by the sponsor.
Study: NCT02156843
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo excipients without the active drug, oral capsule taken BID (twice daily, every 12 hours), until end stage renal disease or death occurs, or the study is terminated by the sponsor.
Study: NCT00005838
Drug: shark cartilage extract AE-941
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT02058186
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03520842
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT00117520
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00336960
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: twice daily beginning 5 days prior to radiotherapy and continuing until completion of radiotherapy
Study: NCT00274105
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00336960
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients receive concurrent fluorouracil IV continuously for 5 weeks.
Study: NCT03770234
Drug: Transtec 35 µg/hour transdermal patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal patch containing 20 mg buprenorphine in an active surface area of 25 squared centimeters. Buprenorphine release rate 35 µg/hour.
Study: NCT00747903
Drug: aminolevulinic acid hydrochloride
Normalized name: Aminolevulinic Acid Hydrochloride
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01241643
Drug: CYT107
Approvals — FDA: no, EMA: no, PMDA: no
Description: repeated cycles of 3 injections of CYT107 at 20 µg/kg/week over 2 weeks, for a maximum of 4 cycles within 21 months and a maximum of 3 cycles within 12 months
Study: NCT02182505
Drug: Berodual® Respimat®, low dose
Approvals — FDA: no, EMA: no, PMDA: no